We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
替诺福韦联合聚乙二醇干扰素α-2b注射液对慢性乙型肝炎患者HBe Ag血清学转换率和阴转率的影响.
- Authors
吴英英; 程聪; 赖文娟; 邱志刚; 张丽
- Abstract
Objective: To investigate the effect of tenofovir combined with peginterferon α-2b injection on HBe Ag seroconversion rate and negative conversion rate in patients with chronic hepatitis B. Methods: From February 2018 to August 2020, 104 cases patients with chronic hepatitis B who were diagnosed and treated in our hospital and Tingzhou hospital were selected as the research objects. All the cases were divided into combination group and a control group with 52 cases each groups accorded to the random number table method. The control group were treated with peginterferon α-2b injection, and the combination group were treated with tenofovir combined with peginterferon α-2b injection. Two groups were treated for 48 weeks. Compare the HBeAg seroconversion and HBV DNA conversion of the patients before and after the correct treatment, and the serum alanine aminotransferase (alanine aminotransferase, ALT) and aspartate aminotransferase (aspartate aminotransferase, AST) levels of the patients. Results: After treatment, the HBe Ag seroconversion rate of the combined group was 11.54 %, which was higher than that of the control group of 3.85 %, but the comparison was not statistically significant (P>0.05). After treatment, the negative rate of HBV DNA in the combined group was 100 %, which was higher than 71.17 % in the control group (P<0.05). The serum ALT and AST values of the two groups after treatment were lower than before treatment (P<0.05), and the combination group were lower than the control group (P<0.05). Conclusion: Tenofovir combined with peginterferon α-2b injection can increase the seroconversion rate and negative conversion rate of HBe Ag in patients with chronic hepatitis B, and improve the liver function of patients.
- Subjects
CHRONIC hepatitis B; ALANINE aminotransferase; ASPARTATE aminotransferase; INTEREST rates; INJECTIONS; DIAGNOSIS
- Publication
Progress in Modern Biomedicine, 2021, Issue 10, p1938
- ISSN
1673-6273
- Publication type
Article
- DOI
10.13241/j.cnki.pmb.2021.10.029